Search Results for: "Other News to Note"
-
Other News To Note
Addex said those results supported efficacy data observed in a preclinical nonhuman primate model of levodopa-induced dyskinesia and will be used to inform the dosing in future clinical studies...The article details the results of a clinical study, in which ORMD-0801 was administered to patients with unstable Type I diabetes, in conjunction with their regular anti-diabetes treatment regimensBioWorld International | Wednesday, May 8, 2013 -
Other News To Note
Further details of the newco will be released later this quarter, though Liquidia said the lead product for the firm will be in glaucoma, with clinical studies expected to start in 2014BioWorld Today | Friday, May 3, 2013 -
Other News To Note
Addex said those results supported efficacy data observed in a preclinical nonhuman primate model of levodopa-induced dyskinesia and will be used to inform the dosing in future clinical studies...The article details the results of a clinical study, in which ORMD-0801 was administered to patients with unstable Type I diabetes, in conjunction with their regular anti-diabetes treatment regimensBioWorld Today | Thursday, May 2, 2013 -
Other News To Note
The pathogen-specific clinical study represents a new development approach to address unmet medical needs for multidrug-resistant bacterial infectionsBioWorld Today | Thursday, April 25, 2013 -
Other News To Note
to begin a Phase IIa trial of BL-8040, a selective antagonist of chemokine receptor CXCR4, in acute myeloid leukemia (AML...According to the terms, Shasun will be able to use the Debiopharm technology to manufacture synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets...In other news, GSK experienced manufacturing delays for manufacture and supply of Horizant (gabapentin enacarbil), partnered with XenoPort Inc., of Santa Clara, CalifBioWorld International | Wednesday, April 17, 2013 -
Pharma: Other News To Note
Approval is based on the results from a clinical study in pediatric patients showing that 81 percent achieved healing during the 12-week treatment period and 90 percent retained healing during the ensuing 24-week extension periodBioWorld Today | Thursday, March 28, 2013 -
Other News To Note
Ltd., of Yokohama, Japan, to use its cell-loading system to support clinical studies and commercialize treatment of cancer patientsBioWorld Today | Thursday, March 28, 2013 -
Other News To Note
In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's sharesBioWorld International | Wednesday, March 27, 2013 -
Other News To Note
The company said it intends to submit a marketing authorization application in Europe with Denmark as the reference member state and contended, based on the positive response in the official minutes of the meeting with the DKMA, that no further clinical studies will be required prior to the submissionBioWorld Today | Wednesday, March 20, 2013 -
Other News To Note
To date, 150 patients out of a total of 200 patients have already been recruited in 16 centers in Germany, Austria and Israel...The goal is to modulate the half-life of the therapy to increase efficacy of treatment...The company intends to start clinical trials in the third quarterBioWorld International | Wednesday, February 27, 2013 -
Other News To Note
Critical Pharmaceuticals Ltd., of Nottingham, UK, completed a second clinical study of CP024, a growth hormone nasal spray in development for growth disorders in children and adultsBioWorld International | Wednesday, February 20, 2013 -
Other News To Note
to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor...In other news, Novartis said the FDA approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemiaBioWorld International | Wednesday, January 30, 2013 -
Other News To Note
CrystalGenomics Inc., of Seoul, South Korea, said it received a draft of the clinical study report from the recently completed Phase IIa study of CG400549, an antibiotic candidate for methicillin-resistant Staphylococcus aureus (MRSA...GlycoVaxyn will work with Janssen's affiliate, Crucell Holland BV, to develop the vaccine until proof of concept, after which Janssen will be responsible for later-stage clinical studies and worldwide commercializationBioWorld International | Wednesday, January 9, 2013 -
Other News To Note
GlycoVaxyn will work with Janssen's affiliate, Crucell Holland BV, to develop the vaccine until proof of concept, after which Janssen will be responsible for later-stage clinical studies and worldwide commercializationBioWorld Today | Monday, January 7, 2013 -
Other News To Note
Savant said it expects to begin clinical studies of the alpha-3-beta-4 nicotinicBioWorld Today | Friday, January 4, 2013 -
Pharma: Other News To Note
Inc., of Whitehouse Station, N.J., and GE Healthcare, of Princeton, N.J., inked a clinical study collaboration, license and supply agreement for the use ofBioWorld Today | Wednesday, December 19, 2012 -
Other News To Note
A further nine patients are expected to be enrolled at three oncological centers in the U.S. Based on the results, the company will implement a clinical study aimed at evaluating the effects of Reparixin, an inhibitor of the CXCR1 receptor activated by chemokine interleukin 8, in oral monotherapy on cancer stem cells and on tumor microenvironment for the treatment of women with early stage breast cancer, before surgeryBioWorld International | Wednesday, December 12, 2012 -
Other News To Note
Arno Therapeutics Inc., of Flemington, N.J., has identified a new immunohistochemistry technique for identifying activated progesterone receptors in breast cancer tumors that may be predictive of response to treatment with onapristone, an investigational progestin receptor antagonist being developed by Arno that has demonstrated antitumor activity in preclinical and clinical studiesBioWorld Today | Friday, December 7, 2012 -
Other News To Note
The contract, issued under the Russian Federation's "Pharma 2020" development initiative, provides matching funding over a period of about three years, which will be used to support preclinical and clinical studiesBioWorld Today | Wednesday, November 28, 2012 -
Other News To Note
Levadex, an inhaled formulation of intravenous drug dihydroergotamine, received a complete response letter following its first submission, with the FDA raising questions relating to chemistry, manufacturing and controls, along with issues relating to a facility inspection at a third-party manufacturer, though no additional clinical studies were requested. (See BioWorld Today, March 28, 2012BioWorld Today | Tuesday, November 27, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.